February 17, 2014Open Access

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

Key Points

Key points are not available for this paper at this time.

Abstract

Canagliflozin improved glycaemic control, reduced body weight and systolic BP, and was generally well tolerated in patients with T2DM on metformin and pioglitazone over 52 weeks.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Thomas Först

Robert Guthrie

Ronald Goldenberg

Journals

Diabetes Obesity and Metabolism

Actions

Institutions

The Ohio State University

Johannes Gutenberg University Mainz

Janssen (United States)

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study